PULMONARY DISEASE (COPD)
Chronic Obstructive Pulmonary Disease (COPD) affects 5-14% of the world population over 40 years of age. Our mission is to reverse the suffering of COPD patients, and provide them with renewed quality of life and hope for the future.
Over 384M Patients
Direct Healthcare Costs of $30B in the USA and €50B in Europe
3rd Leading Cause of Death
Pulsehaler™ is a novel treatment that uses Dynamic Air Pressure Pulses to re-open closed airways,improve exercise capacity and Quality of Life in COPD patients.
NOTE: Pulsehaler is not yet cleared or approved for sale by any regulatory authority.
Yuval Avni, CTO
Serial Entrepreneur, Inventor and Product Developer